Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Renalytix AI is a health information services business based in the US. Renalytix AI shares (RNLX) are listed on the NASDAQ and all prices are listed in US Dollars. Renalytix AI employs 51 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.56 |
|---|---|
| 52-week range | $2.23 - $34.98 |
| 50-day moving average | $4.31 |
| 200-day moving average | $12.23 |
| Wall St. target price | $25.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.21 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.56 from 2022-07-01
| 1 week (2022-06-28) | -36.00% |
|---|---|
| 1 month (2022-06-03) | -43.98% |
| 3 months (2022-04-05) | -61.15% |
| 6 months (2022-01-05) | -83.12% |
| 1 year (2021-07-02) | -90.92% |
|---|---|
| 2 years (2020-07-01) | N/A |
| 3 years (2019-07-01) | N/A |
| 5 years (2017-07-01) | N/A |
| Revenue TTM | $2.4 million |
|---|---|
| Gross profit TTM | $633,000 |
| Return on assets TTM | -29.7% |
| Return on equity TTM | -49.23% |
| Profit margin | 0% |
| Book value | $1.98 |
| Market capitalisation | $95.7 million |
TTM: trailing 12 months
We're not expecting Renalytix AI to pay a dividend over the next 12 months.
Over the last 12 months, Renalytix AI's shares have ranged in value from as little as $2.23 up to $34.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Renalytix AI's is 1.5915. This would suggest that Renalytix AI's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.